C4 Therapeutics
C4 is building on the knowledge with synthetic chemical compounds.
Launch date
Employees
Market cap
€406m
Enterprise valuation
€228m (Public information from Sep 2024)
Share price
$6.57 CCCC
Watertown Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 33.2m | 45.8m | 31.1m | 20.8m | 28.5m | 20.9m | 17.3m |
| % growth | 55 % | 38 % | (32 %) | (33 %) | 37 % | (27 %) | (17 %) |
| EBITDA | (58.4m) | (80.3m) | (126m) | (127m) | (82.2m) | (98.6m) | (114m) |
| % EBITDA margin | (176 %) | (175 %) | (405 %) | (614 %) | (289 %) | (473 %) | (657 %) |
| Profit | (66.3m) | (83.9m) | (128m) | (132m) | (105m) | (131m) | (156m) |
| % profit margin | (200 %) | (183 %) | (412 %) | (638 %) | (369 %) | (630 %) | (901 %) |
| EV / revenue | 32.0x | 32.8x | 0.7x | 1.2x | 4.7x | 7.3x | 7.2x |
| EV / EBITDA | -18.2x | -18.7x | -0.2x | -0.2x | -1.6x | -1.6x | -1.1x |
| R&D budget | 78.4m | 94.7m | 118m | 118m | - | - | - |
| R&D % of revenue | 236 % | 207 % | 379 % | 567 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$73.0m | Series A | ||
$20.0m | Debt | ||
| $150m | Series B | |
| N/A | N/A | IPO | |
| Total Funding | €203m | ||
Recent News about C4 Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.